Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study

NCT ID: NCT00672035

Last Updated: 2012-03-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 406 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-10-31
• Study Completion Date: 2008-07-31

Brief Summary

The main purpose of this study is to evaluate the body's immune response to the LT patch at different doses.

The secondary purpose of this study is to evaluate the safety of the LT patches at different doses and the safety of the skin preparation system. Another secondary purpose is to compare the safety and the body's immune response to LT patches placed on the upper arm versus the lower back.

Detailed Description

This is a randomized, double-blind, placebo-controlled, dose ranging, multicenter study. Subjects will be assigned to one of ten treatment groups and vaccinated according to the study group designation. Treatments will remain the same for first and second vaccinations (alternating left and right sides).

Conditions

Traveler's Diarrhea

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

1

7.5µg LT Dose placed at the Deltoid on Day 0 and Day 21

Group Type: EXPERIMENTAL

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

2

7.5µg LT Dose placed at the Lower Back on Day 0 and Day 21

Group Type: EXPERIMENTAL

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

3

22.5µg LT Dose placed at the Deltoid on Day 0 and Day 21

Group Type: EXPERIMENTAL

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

4

22.5µg LT Dose placed at the Lower Back on Day 0 and Day 21

Group Type: EXPERIMENTAL

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

5

37.5µg LT Dose placed at the Deltoid on Day 0 and Day 21

Group Type: EXPERIMENTAL

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

6

37.5µg LT Dose placed at the Lower Back on Day 0 and Day 21

Group Type: EXPERIMENTAL

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

7

50µg LT Dose placed at the Deltoid on Day 0 and Day 21

Group Type: EXPERIMENTAL

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

8

50µg LT Dose placed at the Lower Back on Day 0 and Day 21

Group Type: EXPERIMENTAL

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

9

Placebo (0µg LT) placed at the Deltoid on Day 0 and Day 21

Group Type: PLACEBO_COMPARATOR

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

10

Placebo (0µg LT) placed at the Lower Back on Day 0 and Day 21

Group Type: PLACEBO_COMPARATOR

Biological: heat-labile enterotoxin of E. coli (LT)

Intervention Type: BIOLOGICAL

LT patch applied on either the deltoid or the lower back.

Interventions

Biological: heat-labile enterotoxin of E. coli (LT)

LT patch applied on either the deltoid or the lower back.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Healthy adult males or females 18 to 40 years of age with signed informed consent.
• Women who are not post-menopausal or surgically sterile must have a negative serum or urine pregnancy test at screening and within 24 hours prior to each vaccination with understanding (through informed consent process) to not become pregnant over the duration of the study, and must agree to employ an effective form of birth control for the duration of the study.
• Acceptable forms of birth control are: abstinence, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom, diaphragm with spermicide), and IUD.

Subjects meeting any of the following criteria are not eligible for participation in the study:

Exclusion Criteria

• Laboratory abnormalities.
• Abnormalities at physical examination
• Known allergies to any component of the vaccine.
• Known disturbance of coagulation.
• Known allergies to adhesives.
• Participated in unrelated research involving investigational product within 30 days before planned date of first vaccination.
• Ever received investigational enterotoxigenic E. coli, LT, or LT(R192G) or NasalFlu, Berna Biotech, Ltd.
• Ever received cholera toxin or vaccine (e.g. Orochol™, Dukoral™).
• Medical history of acute or chronic skin disease at vaccination site(s).
• Active skin allergy.
• Recent or regular use of oral or injected steroid medications.
• Use of immunosuppressive systemic steroid medications including inhaled steroids within three months prior to first vaccination.
• Comorbid conditions or treatments that are immunosuppressive, including cancer, diabetes, end-stage renal disease, as determined by the Investigator.
• Positive serology for HIV-1, HIV-2, HBsAg, or HCV.
• History of severe atopy. Signs or history of acute skin infection, sunburn or skin abnormalities on the vaccination area(s) including fungal infections, severe acne, history of keloid formation, or active contact dermatitis.
• Artificial tanning (UV radiation) over the duration of the study including the screening period.
• Hirsute (significant amount of hair) at vaccination area(s).
• Visible tattoos or marks (tattoos/scars) at the vaccination area(s) that would prevent appropriate dermatological monitoring of the vaccination site(s).
• Fever equal to or greater than 38.0°C (≥100.4°F) at the time of planned vaccination.
• Suspicion of or recent history of alcohol or substance abuse.
• Donated blood or blood products such as plasma within the past 30 days.
• Women who are pregnant or breastfeeding.
• Employee of the investigational site.
• Medical history of achlorhydria.
• History of abdominal surgery (excluding C-section, hysterectomy, cosmetic surgery, liposuction, appendectomy, cholecystectomy, ventral hernia repair, and other surgeries not pertaining to gastrointestinal problems) or history of, or recent acute gastrointestinal illness.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Intercell USA, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael J Noss, MD

Role: PRINCIPAL_INVESTIGATOR

Radiant Research, Cincinnati

Locations

Solano Clinical Research

Davis, California, United States

QUEST Research Institute

Bingham Farms, Michigan, United States

Asthma and Allergy Associates PC

Cortland, New York, United States

Radiant Research - Cincinnati

Cincinnati, Ohio, United States

Clinical Trials of Texas

San Antonio, Texas, United States

Countries

United States

Other Identifiers

ELT202

Identifier Type: -

Identifier Source: org_study_id